Topotecan (Hycamtin)
Indications
- Cervical Cancer (see Cervical Cancer, [[Cervical Cancer]])
- Ovarian Cancer (see Ovarian Cancer, [[Ovarian Cancer]])
- Pediatric Sarcoma
- Small Cell Lung Cancer (see Lung Cancer, [[Lung Cancer]]): approved as single-agent chemotherapy for recurrent disease -> 20% response rate
Pharmacology
- Oral Topoisomerase I Inhibitor: camptothecin derivative
Metabolism
Administration
Dose Adjustment
Adverse Effects
Hematologic Adverse Effects
- Myelosuppression
- Anemia (see Anemia, [[Anemia]]): 33% of cases
- Leukopenia (see Leukopenia, [[Leukopenia]]): 90% of cases
- Thrombocytopenia (see Thrombocytopenia, [[Thrombocytopenia]]): 55% of cases
Pulmonary Adverse Effects
Other Adverse Effects
References
- Rossi SE. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-1259
- Topotecan-induced Bronchiolitis. Southern Medical Journal: July 2004 – Volume 97 – Issue 7 – pp 699-701